Abstract: A method for preparing an activated expanded lymphocyte stock solution includes co-culturing, in a serum-free medium, a lymphocyte activator with peripheral blood mononuclear cells obtained via autologous peripheral whole blood centrifugal extraction, and thus completing lymphocyte culture activation. The cultured activated lymphocytes are placed into a serum-free medium. Subculturing is performed to prepare lymphocyte activation culture. A serum-free medium having a volume which is 5 to 10 times of the lymphocyte activation culture is added to the lymphocyte activation culture. Expansion culture is performed, wherein the number of expansion culture generations is 1 to 5. A step of centrifuging, washing, and collecting the activated expanded lymphocytes is performed.

Abstract: Methods and compositions are provided for the treatment of virus infections in a subject which can be a human subject. The methods include administering one or more doses of a composition comprising therapeutic double-stranded RNA (tdsRNA) to a subject after active viral replication in the nasal passages of the subject. Following administration, the tdsRNA induces an enhanced and cross protective immune response to the virus or a broad-based immune response to the virus and variants thereof.

Abstract: Disclosed is a method for treating a subject that has previously been infected with SARS-COV-2 and exhibiting at least one Post COVID-19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

Abstract: A starch-indole-acid derivative, a preparation method therefor, and a use thereof are provided. The starch-indole-acid derivative refers to esterified starch generated by starch undergoing an esterification reaction together with indole acid under the action of a condensing agent and a base. The derivative has high resistance and can resist degradation in the stomach and small intestine. After reaching the colon, the derivative can be fermented by intestinal flora to release indole acid, which is beneficial to intestinal health. The starch-indole-acid derivative has significant advantages and can significantly increase the content of indole acid in colon and hepatic portal blood.

Abstract: Methods and compositions for treating, reducing, or preventing neuroinflammation in a subject in need thereof. The methods comprise, at least, a step of administering to a subject a therapeutically effective amount of Therapeutic Double-Stranded RNA. The compositions comprise at least a therapeutically effective amount of Therapeutic Double-Stranded RNA.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).

Abstract: This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal ?-interferon.

Abstract: Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.

Abstract: Disclosed is a method for the synthesis of a therapeutic double-stranded RNA (tdsRNA), comprising: a) synthesizing a first single-stranded RNA (first ssRNA) in a first synthesis reaction with PNPase as the only RNA polymerase; b) synthesizing a second single-stranded RNA (second ssRNA) in a second synthesis reaction with PNPase as the only RNA polymerase; and c) hybridizing the first ssRNA with the second ssRNA to form the tdsRNA; wherein step a) and step b) are performed in any order. Also disclosed is a product produced by the method.

Abstract: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).

Abstract: This disclosure relates to a method of treating, preventing, or reducing a symptom of a virus infection, including a SARS-CoV-2 infection, by administering an effective amount of tdsRNA optionally with an anti-viral agent, to a subject.

Abstract: Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.

Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.

Abstract: This disclosure relates to compositions and methods for treating a subject previously infected with a virus and afflicted with post viral fatigue symptoms such as, for example, Long Covid. The compositions and methods comprise a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA tdsRNA.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

Abstract: The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.